Wire · opportunities
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
The FDA has approved Eli Lilly's Mounjaro (tirzepatide) to lower the risk of major cardiovascular events in adults with type 2 diabetes at high risk, based on results from the large SURPASS-CVOT trial showing non-inferiority and an 8% lower rate of cardiovascular death, heart attack, or stroke compared to Trulicity.
This Wire brief sits within Fusion42's coverage of Health, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You face a regulatory green light to promote Mounjaro as a solution that also cuts heart risks in type 2 diabetes, opening opportunities in cardiovascular care beyond sugar control. Rival products now compete on cardiovascular proof, so position your next moves around integrated patient outcomes.
◆ Coverage
2 sources · 28 Aug 2026
◆ Related on Wire
◆ Topics